{"transactions":[{"id":4635654,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":184215,"kind":"person","name":"Houvras Yariv","position":1,"cik":"0002154870","reported_name":"Houvras Yariv","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:33:12.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter."}],"balance_after":105000,"derivative":{"exercise_price":8.91,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001193125-26-412466","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526412466/ownership.xml","form_type":"4"}},{"id":739022,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:08.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269401","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526269401/ownership.xml","form_type":"4"}},{"id":739021,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:07.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269398","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526269398/ownership.xml","form_type":"4"}},{"id":739122,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:05.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000119312526269397/ownership.xml","form_type":"4"}},{"id":739177,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":25936,"kind":"person","name":"Bonstein Sara","position":1,"cik":"0001604019","reported_name":"Bonstein Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:04.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269396","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604019/000119312526269396/ownership.xml","form_type":"4"}},{"id":739129,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:02.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269395","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000119312526269395/ownership.xml","form_type":"4"}},{"id":740330,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38906,"kind":"person","name":"Bello Akintunde Olatokumbo","position":1,"cik":"0002070709","reported_name":"Bello Akintunde Olatokumbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T16:07:11.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2070709/000119312526269399/ownership.xml","form_type":"4"}},{"id":739755,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38717,"kind":"person","name":"Shannon James Samuel","position":1,"cik":"0001485417","reported_name":"Shannon James Samuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T16:07:09.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269400","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485417/000119312526269400/ownership.xml","form_type":"4"}},{"id":806934,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-16T21:12:22.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":8.4,"expiration_date":"2036-04-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-159316","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000119312526159316/ownership.xml","form_type":"4"}},{"id":825228,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38717,"kind":"person","name":"Shannon James Samuel","position":1,"cik":"0001485417","reported_name":"Shannon James Samuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-30T17:29:01.000Z","date":"2026-03-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":8.79,"value":43950.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $8.6758 to $9.2499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares beneficially owned reflects the 1-for-14 reverse stock split effected March 13, 2026."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-131745","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485417/000119312526131745/ownership.xml","form_type":"4"}},{"id":313703,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Prefunded Warrants (right to buy)","published_at":"2026-02-17T22:31:38.000Z","date":"2026-02-13","kind":"purchase","planned":false,"acquired":true,"shares":3739000,"price":0.5349,"value":1999991.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer."}],"balance_after":40384266,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3739000},"source":{"system":"sec-edgar","filing":"0001123292-26-000187","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112329226000187/form4.xml","form_type":"4"}},{"id":949732,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:30:23.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-002518","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002518/ownership.xml","form_type":"4"}},{"id":949731,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:30:23.000Z","date":"2025-12-31","kind":"grant","planned":true,"acquired":true,"shares":95221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 3 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met."},{"field":"shares","element":"transactionShares","label":"F4","text":"The portion of Tranche 3 Options that achieved the vesting condition s equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":95221,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":95221},"source":{"system":"sec-edgar","filing":"0001193125-26-002518","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002518/ownership.xml","form_type":"4"}},{"id":949730,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Common Stock","published_at":"2026-01-05T21:30:23.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":1826,"price":0.6432,"value":1174.4832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of 1,826 shares occurred automatically in a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":6371,"source":{"system":"sec-edgar","filing":"0001193125-26-002518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002518/ownership.xml","form_type":"4"}},{"id":949729,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Common Stock","published_at":"2026-01-05T21:30:23.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."}],"balance_after":8197,"source":{"system":"sec-edgar","filing":"0001193125-26-002518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002518/ownership.xml","form_type":"4"}},{"id":949728,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:30:21.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":false,"shares":19375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."}],"balance_after":38750,"derivative":{"underlying":"Common Stock","underlying_shares":19375},"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":949727,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:30:21.000Z","date":"2025-12-31","kind":"grant","planned":true,"acquired":true,"shares":668789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 3 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met."},{"field":"shares","element":"transactionShares","label":"F4","text":"The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":668789,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":668789},"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":949726,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:30:21.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":7030,"price":0.6432,"value":4521.696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of 7,030 shares occurred automatically in a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":24766,"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":949725,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:30:21.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":true,"shares":19375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."}],"balance_after":31796,"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":952137,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T16:30:26.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":false,"shares":16625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."}],"balance_after":33250,"derivative":{"underlying":"Common Stock","underlying_shares":16625},"source":{"system":"sec-edgar","filing":"0001193125-26-002520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312526002520/ownership.xml","form_type":"4"}},{"id":952136,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T16:30:26.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":451885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 3 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The portion of Tranche 3 Options that achieved  the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":451885,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":451885},"source":{"system":"sec-edgar","filing":"0001193125-26-002520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312526002520/ownership.xml","form_type":"4"}},{"id":952135,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:26.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":16625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."}],"balance_after":33250,"source":{"system":"sec-edgar","filing":"0001193125-26-002520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312526002520/ownership.xml","form_type":"4"}},{"id":949848,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T16:30:18.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":false,"shares":44250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."}],"balance_after":88500,"derivative":{"underlying":"Common Stock","underlying_shares":44250},"source":{"system":"sec-edgar","filing":"0001193125-26-002512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312526002512/ownership.xml","form_type":"4"}},{"id":949847,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T16:30:18.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":1500258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 3 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":1500258,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":1500258},"source":{"system":"sec-edgar","filing":"0001193125-26-002512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312526002512/ownership.xml","form_type":"4"}},{"id":949846,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:18.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":44250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."}],"balance_after":325422,"source":{"system":"sec-edgar","filing":"0001193125-26-002512","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312526002512/ownership.xml","form_type":"4"}},{"id":316662,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-12-01T21:36:41.000Z","date":"2025-11-26","kind":"other","planned":false,"acquired":false,"shares":13335000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the Series B Warrants was $0.75 per share of Common Stock. Because the Reporting Person chose to receive Prefunded Warrants in lieu of Common Stock upon exercise of the Series B Warrants, the exercise price was $0.75 less $0.0001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Warrants were exercisable at any time on or after November 1, 2025 and would have expired on December 2, 2025, provided that if the closing price of the Common Stock was below the exercise price on such date, the exercise price would have reset to the closing price on December 1, 2025 and the expiration time would have been extended to December 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":0.7499,"exercise_date":"2025-11-01","underlying":"Common Stock","underlying_shares":13335000},"source":{"system":"sec-edgar","filing":"0001123292-25-000675","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112329225000675/form4.xml","form_type":"4"}},{"id":316661,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Prefunded Warrants (right to buy)","published_at":"2025-12-01T21:36:41.000Z","date":"2025-11-26","kind":"other","planned":false,"acquired":true,"shares":13335000,"price":0.7499,"value":9999916.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date."}],"balance_after":36645266,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":13335000},"source":{"system":"sec-edgar","filing":"0001123292-25-000675","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112329225000675/form4.xml","form_type":"4"}},{"id":988292,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 1, 2024. The shares underlying the option began vesting on June 1, 2024 and continue to vest in equal monthly installments thereafter through May 1, 2028."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-25-297207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297207/ownership.xml","form_type":"4"}},{"id":988291,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 1, 2024. The shares underlying the option began vesting on June 1, 2024 and continue to vest in equal monthly installments thereafter through May 1, 2028."}],"balance_after":0,"derivative":{"exercise_price":1.08,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-25-297207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297207/ownership.xml","form_type":"4"}},{"id":988290,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."}],"balance_after":25000,"derivative":{"exercise_price":1,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-297207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297207/ownership.xml","form_type":"4"}},{"id":988289,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-297207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297207/ownership.xml","form_type":"4"}},{"id":988288,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on April 1, 2023 and vested on March 30, 2024 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through March 30, 2027."}],"balance_after":55000,"derivative":{"exercise_price":1,"expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001193125-25-297207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297207/ownership.xml","form_type":"4"}},{"id":988287,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on April 1, 2023 and vested on March 30, 2024 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through March 30, 2027."}],"balance_after":0,"derivative":{"exercise_price":3.17,"expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001193125-25-297207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297207/ownership.xml","form_type":"4"}},{"id":988286,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70235,"kind":"person","name":"Brennan Kevin M.","position":1,"cik":"0001971303","reported_name":"Brennan Kevin M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE AND ACCOUNTING"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":131700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 1 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":131700,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":131700},"source":{"system":"sec-edgar","filing":"0001193125-25-297207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297207/ownership.xml","form_type":"4"}},{"id":988284,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":300000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988283,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988282,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on August 3, 2023. The shares underlying the option began vesting on September 1, 2023 and continue to vest in equal monthly installments thereafter through August 1, 2027."}],"balance_after":150000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-08-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988281,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on August 3, 2023. The shares underlying the option began vesting on September 1, 2023 and continue to vest in equal monthly installments thereafter through August 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.75,"expiration_date":"2033-08-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988280,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":117000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":117000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988279,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":117000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.69,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988278,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on September 1, 2022. The shares underlying the option began vesting on September 1, 2022 and continue to vest in equal monthly installments thereafter through August 1, 2026."}],"balance_after":20000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988277,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on September 1, 2022. The shares underlying the option began vesting on September 1, 2022 and continue to vest in equal monthly installments thereafter through August 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":2.13,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988276,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":45000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988275,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":12.66,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988274,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":37296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":37296,"derivative":{"exercise_price":1.5,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":37296},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988273,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":37296},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988272,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":23786,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":23786,"derivative":{"exercise_price":1.5,"expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":23786},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988271,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23786,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.65,"expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":23786},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988270,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":false,"shares":155090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":155090,"derivative":{"exercise_price":1.5,"expiration_date":"2031-03-28","underlying":"Common Stock","underlying_shares":155090},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988269,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":155090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.65,"expiration_date":"2031-03-28","underlying":"Common Stock","underlying_shares":155090},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988268,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":925000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 1 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":925000,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":925000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988887,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":106000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on September 5, 2023. The shares underlying the option began vesting on October 1, 2023 and continue to vest in equal monthly installments thereafter through September 1, 2027."}],"balance_after":106000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-09-04","underlying":"Common Stock","underlying_shares":106000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988886,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":106000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on September 5, 2023. The shares underlying the option began vesting on October 1, 2023 and continue to vest in equal monthly installments thereafter through September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.79,"expiration_date":"2033-09-04","underlying":"Common Stock","underlying_shares":106000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988885,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Immediately exercisable."}],"balance_after":25000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988884,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988883,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988882,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.69,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988881,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on November 1, 2022. The shares underlying the option began vesting on December 1, 2022 and continue to vest in equal monthly installments thereafter through November 1, 2026."}],"balance_after":15000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-10-31","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988880,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on November 1, 2022. The shares underlying the option began vesting on December 1, 2022 and continue to vest in equal monthly installments thereafter through November 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":2.37,"expiration_date":"2032-10-31","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988879,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":44210,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 7, 2021 and vested on December 2, 2022 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through December 2, 2025."}],"balance_after":44210,"derivative":{"exercise_price":1.5,"expiration_date":"2031-12-06","underlying":"Common Stock","underlying_shares":44210},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988878,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44210,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 7, 2021 and vested on December 2, 2022 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through December 2, 2025."}],"balance_after":0,"derivative":{"exercise_price":9.69,"expiration_date":"2031-12-06","underlying":"Common Stock","underlying_shares":44210},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988877,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70369,"kind":"person","name":"Luptakova Katarina","position":1,"cik":"0001991149","reported_name":"Luptakova Katarina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:04.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 1 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":625000,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001193125-25-297205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991149/000119312525297205/ownership.xml","form_type":"4"}},{"id":988339,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":700000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988338,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988337,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":350000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988336,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.69,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988335,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":150000,"derivative":{"exercise_price":1.5,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988334,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":12.66,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988333,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 22, 2021. The shares underlying the option began vesting on January 1, 2022 and continue to vest in equal monthly installments thereafter through December 1, 2025."}],"balance_after":100000,"derivative":{"exercise_price":1.5,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988332,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 22, 2021. The shares underlying the option began vesting on January 1, 2022 and continue to vest in equal monthly installments thereafter through December 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":13.83,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988331,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":50041,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":50041,"derivative":{"exercise_price":1.5,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":50041},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988330,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50041,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":50041},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988329,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":135134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":135134,"derivative":{"exercise_price":1.5,"expiration_date":"2031-08-22","underlying":"Common Stock","underlying_shares":135134},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988328,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.69,"expiration_date":"2031-08-22","underlying":"Common Stock","underlying_shares":135134},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988327,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":473334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":473334,"derivative":{"exercise_price":1.5,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":473334},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988326,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":473334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.89,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":473334},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988325,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":239703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":239703,"derivative":{"exercise_price":1.5,"expiration_date":"2030-07-22","underlying":"Common Stock","underlying_shares":239703},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988324,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":239703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.51,"expiration_date":"2030-07-22","underlying":"Common Stock","underlying_shares":239703},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988323,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":2075000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 1 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":2075000,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":2075000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":1106231,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38717,"kind":"person","name":"Shannon James Samuel","position":1,"cik":"0001485417","reported_name":"Shannon James Samuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T16:57:19.000Z","date":"2025-06-17","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":0.6886,"value":17215.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6659 to $0.6991 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001415889-25-017705","document":"form4-06182025_080615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1485417/000141588925017705/form4-06182025_080615.xml","form_type":"4"}},{"id":1106230,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38717,"kind":"person","name":"Shannon James Samuel","position":1,"cik":"0001485417","reported_name":"Shannon James Samuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T16:57:19.000Z","date":"2025-06-16","kind":"purchase","planned":false,"acquired":true,"shares":45000,"price":0.686,"value":30870.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6799 to $0.6891 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001415889-25-017705","document":"form4-06182025_080615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485417/000141588925017705/form4-06182025_080615.xml","form_type":"4"}},{"id":1105895,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-06-18T16:56:47.000Z","date":"2025-06-16","kind":"purchase","planned":false,"acquired":true,"shares":36289,"price":0.6801,"value":24680.1489,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6551 to $0.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":281172,"source":{"system":"sec-edgar","filing":"0001415889-25-017704","document":"form4-06182025_080644.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588925017704/form4-06182025_080644.xml","form_type":"4"}},{"id":1112813,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:37:36.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016972","document":"form4-06122025_080633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000141588925016972/form4-06122025_080633.xml","form_type":"4"}},{"id":1112817,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:37:15.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016971","document":"form4-06122025_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000141588925016971/form4-06122025_080611.xml","form_type":"4"}},{"id":1112877,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":25936,"kind":"person","name":"Bonstein Sara","position":1,"cik":"0001604019","reported_name":"Bonstein Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:36:54.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016970","document":"form4-06122025_080651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604019/000141588925016970/form4-06122025_080651.xml","form_type":"4"}},{"id":1112777,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:36:32.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016969","document":"form4-06122025_080628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925016969/form4-06122025_080628.xml","form_type":"4"}},{"id":1113183,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":33396,"kind":"person","name":"Clancy Paul J","position":1,"cik":"0001409601","reported_name":"Clancy Paul J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:36:08.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016968","document":"form4-06122025_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1409601/000141588925016968/form4-06122025_080604.xml","form_type":"4"}},{"id":1112776,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:35:42.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016967","document":"form4-06122025_080636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925016967/form4-06122025_080636.xml","form_type":"4"}},{"id":1112812,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:34:52.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016964","document":"form4-06122025_080649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756941/000141588925016964/form4-06122025_080649.xml","form_type":"4"}},{"id":1113291,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38717,"kind":"person","name":"Shannon James Samuel","position":1,"cik":"0001485417","reported_name":"Shannon James Samuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T16:35:17.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016966","document":"form4-06122025_080613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485417/000141588925016966/form4-06122025_080613.xml","form_type":"4"}},{"id":1113856,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38906,"kind":"person","name":"Bello Akintunde Olatokumbo","position":1,"cik":"0002070709","reported_name":"Bello Akintunde Olatokumbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T16:34:26.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 10, 2025 and will vest in three equal installments on June 10, 2026, June 10, 2027 and June 10, 2028, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":62000,"derivative":{"exercise_price":0.7,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0001415889-25-016962","document":"form4-06122025_080623.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2070709/000141588925016962/form4-06122025_080623.xml","form_type":"4"}},{"id":321614,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrants (right to buy)","published_at":"2025-06-06T23:31:28.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":13335000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series C Warrants are exercisable at any time on or after June 1, 2026 and expire on the earlier of (i) December 2, 2026 and (ii) the expiration time of the Series B Warrants held by the reporting person to the extent that the corresponding Series B Warrants expire without being exercised, but with respect to only that number of Series C Warrants that is equal to the number of Series B Warrants that expire without being exercised. In addition, if the closing price of the Common Stock is below the exercise price on December 2, 2026, the exercise price will reset to the closing price on December 1, 2026 and the expiration time will be extended to December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series C Warrants are exercisable at any time on or after June 1, 2026 and expire on the earlier of (i) December 2, 2026 and (ii) the expiration time of the Series B Warrants held by the reporting person to the extent that the corresponding Series B Warrants expire without being exercised, but with respect to only that number of Series C Warrants that is equal to the number of Series B Warrants that expire without being exercised. In addition, if the closing price of the Common Stock is below the exercise price on December 2, 2026, the exercise price will reset to the closing price on December 1, 2026 and the expiration time will be extended to December 31, 2026."}],"balance_after":13335000,"derivative":{"exercise_price":0.75,"underlying":"Common Stock","underlying_shares":13335000},"source":{"system":"sec-edgar","filing":"0001062993-25-011170","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299325011170/form4.xml","form_type":"4"}},{"id":321613,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2025-06-06T23:31:28.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":13335000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B Warrants are exercisable at any time on or after November 1, 2025 and expire on December 2, 2025, provided that if the closing price of the Common Stock is below the exercise price on such date, the exercise price will reset to the closing price on December 1, 2025 and the expiration time will be extended to December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Warrants are exercisable at any time on or after November 1, 2025 and expire on December 2, 2025, provided that if the closing price of the Common Stock is below the exercise price on such date, the exercise price will reset to the closing price on December 1, 2025 and the expiration time will be extended to December 31, 2025."}],"balance_after":13335000,"derivative":{"exercise_price":0.75,"underlying":"Common Stock","underlying_shares":13335000},"source":{"system":"sec-edgar","filing":"0001062993-25-011170","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299325011170/form4.xml","form_type":"4"}},{"id":321612,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2025-06-06T23:31:28.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":13335000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A Warrants will be exercisable at any time on or after the earlier of (i) December 1, 2025 and (ii) the trading day immediately following a period of five consecutive trading days on which the closing price of the Common Stock is a minimum of $1.50 per share and will expire on the earlier of (A) June 5, 2030 and (B) immediately upon exercise of the reporting person's Prefunded Warrants issued on June 5, 2025 if such exercise is prior to December 1, 2025, but with respect to only that number of Series A Warrants that is equal to the number of Prefunded Warrants that are exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Warrants will be exercisable at any time on or after the earlier of (i) December 1, 2025 and (ii) the trading day immediately following a period of five consecutive trading days on which the closing price of the Common Stock is a minimum of $1.50 per share and will expire on the earlier of (A) June 5, 2030 and (B) immediately upon exercise of the reporting person's Prefunded Warrants issued on June 5, 2025 if such exercise is prior to December 1, 2025, but with respect to only that number of Series A Warrants that is equal to the number of Prefunded Warrants that are exercised."}],"balance_after":13335000,"derivative":{"exercise_price":0.75,"underlying":"Common Stock","underlying_shares":13335000},"source":{"system":"sec-edgar","filing":"0001062993-25-011170","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299325011170/form4.xml","form_type":"4"}},{"id":321611,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Prefunded Warrants (right to buy)","published_at":"2025-06-06T23:31:28.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":13335000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the \"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date."}],"balance_after":23310266,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":13335000},"source":{"system":"sec-edgar","filing":"0001062993-25-011170","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299325011170/form4.xml","form_type":"4"}},{"id":1170759,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-16T20:30:14.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 15, 2025 and will vest in equal monthly installments beginning on May 1, 2025 through April 1, 2029."}],"balance_after":75000,"derivative":{"exercise_price":0.712,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-25-010804","document":"form4-04162025_040404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925010804/form4-04162025_040404.xml","form_type":"4"}},{"id":1170800,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-16T16:30:17.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 15, 2025 and will vest in equal monthly installments beginning on May 1, 2025 through April 1, 2029."}],"balance_after":190000,"derivative":{"exercise_price":0.712,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001415889-25-010805","document":"form4-04162025_040405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588925010805/form4-04162025_040405.xml","form_type":"4"}},{"id":1313128,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:15:19.000Z","date":"2025-01-01","kind":"grant","planned":true,"acquired":true,"shares":251000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029."}],"balance_after":251000,"derivative":{"exercise_price":0.955,"expiration_date":"2035-12-31","underlying":"Common Stock","underlying_shares":251000},"source":{"system":"sec-edgar","filing":"0001415889-25-000407","document":"form4-01032025_040116.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925000407/form4-01032025_040116.xml","form_type":"4"}},{"id":1313127,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T21:15:19.000Z","date":"2025-01-01","kind":"exercise","planned":true,"acquired":false,"shares":19375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs) convert to stock on a one-for-one basis"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."}],"balance_after":58125,"derivative":{"underlying":"Common Stock","underlying_shares":19375},"source":{"system":"sec-edgar","filing":"0001415889-25-000407","document":"form4-01032025_040116.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925000407/form4-01032025_040116.xml","form_type":"4"}},{"id":1313126,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-01-03T21:15:19.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":6954,"price":0.9837,"value":6840.6498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of 6,954 shares occurred automatically in a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":12421,"source":{"system":"sec-edgar","filing":"0001415889-25-000407","document":"form4-01032025_040116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925000407/form4-01032025_040116.xml","form_type":"4"}}],"next_cursor":"2025-01-03T21:15:19.000000Z,1313126"}